← Trials/Trial dossier/NCT07167966

ATP

Enrolling by invitationPhase 2

Alzheimer's Tau Platform: Regimen A - AADvac1

Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1

Lead sponsor

Paul S. Aisen

Assets

AADvac1 / Donanemab

Listed sites

Recruiting sites

Enrollment

450

estimated

Study population

Alzheimer’s disease

Key I/E criterion

•Age 50-80

Primary endpoint

•Brain tau deposition

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDATRI-014-A

NCT IDNCT07167966

Timeline

Milestones

Study first posted2025-09-11actual

Last update posted2026-07-09actual

Study start2026-11-03estimated

Primary completion2028-08-31estimated

Study completion2028-08-31estimated

Assets

Drug assets

AADvac1 Donanemab

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT06957418)

Exclusion criteria

•No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol (NCT06957418).

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Disease progression

Tau biomarkers

Disease progression

1 endpoint

Secondary/protocol endpoint

Disease progression as measured by plasma biomarkers

Time frame:30 months

descriptive

Tau biomarkers

1 endpoint

Primary/protocol endpoint

Reduction of brain tau deposition as measured by tau positron emission tomography (PET)

Time frame:0, 6, 18 and 30 months

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.